Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q3 EPS of ($0.74), $0.24 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $0 versus the consensus estimate of $1.38 million.

For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.